Skip to main content
TWST logo

TWST

Twist Bioscience Corp
$99.24 -3.01 (-2.94%) At close · Jul 2
Market Cap
$6.18B
Shares
62,271,314

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-05-27 Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the

2026-05-05 Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 5, 2026-- As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of

2026-05-04 Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics SOUTH

2026-05-04 Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 4, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026.

2026-04-21 Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026

Company to host conference call at 8:00 AM ET Investor Day Scheduled for May 21, 2026 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 21, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for

2026-02-18 Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 18, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate

2026-02-17 Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

B-Body ® platform complements Twist’s antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery

2026-02-10 Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

Twist TrueAmp Library Preparation Kit with in-house developed enzymes including new Twist TrueAmp Polymerase Twist PCR-Free WGS Library Preparation Kit designed to meet the needs of the growing whole genome sequencing market New kits compatible with additional Twist NGS Applications tools for

2026-02-03 Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 3, 2026-- As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 114,869 equity awards, consisting of

2026-02-02 Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 2, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025.

Past events

Source: https://investors.twistbioscience.com/

Key facts CIK 1581280 CUSIP 90184D100 13F (30d) 2 filings 2 filers Visit website Investor relations